Regeneron Pharmaceuticals Inc. (REGN)

NASDAQ: REGN · USD

$656

+4.11 (+0.6%)· Recorded snapshot

Coverage state: Latest published research available

Market snapshot recorded 2026-07-27 02:00 UTC. Latest published research analyzed 2026-05-10 · stale · sources unverified. Prices and fundamentals on this server-rendered page are dated snapshots, not a real-time trading feed.

On-demand research

Generate a fresh REGN analysis

The published report stays available while a new owner-requested analysis runs.

StockMarketAgent Research · Analyzed 2026-05-10

Our latest published analysis: REGN rated Strong Buy

REGN is rated Strong Buy at $714.89 versus the reconciled fair value midpoint of $1,209.72, implying +69.22% upside/downside. Confidence is separately disclosed at 88/100.

Fair value (mid)

$1,210 / share

$917 – $1,505

Upside to FV

+69.2%

from $656

Confidence

88/100

Moat

9/10

Market cap	$74.9B
Revenue (ttm)	14.9B
Net income (ttm)	4.4B
EPS (ttm)	$41.1
Shares out	101.7M
P/E (trailing)	16.0x
P/E (forward)	13.3x
Dividend	$3.76 (0.57%)
Volume	708,346
Beta	0.24
Price target	$819	+24.9%

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 14.9B
Net income (ttm): 4.4B
EPS (ttm): $41.1
P/E (trailing): 16.0x
P/E (forward): 13.3x
Market cap: $74.9B

Item	P1	P2	P3	P4	P5	Trend
Period	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31	Trend
Revenue	—	$12.17B	$13.12B	$14.20B	$14.34B	+4.2%
Gross profit	—	$10.61B	$11.30B	$12.23B	$12.24B	+3.6%
Operating income	—	$4.74B	$4.05B	$3.99B	$3.70B	-6.0%
Net income	—	$4.34B	$3.95B	$4.41B	$4.50B	+0.9%
EPS (diluted)	$71.97	$38.22	$34.77	$38.34	$41.48	-12.9%
EBITDA	—	$5.26B	$4.69B	$5.32B	$5.82B	+2.6%
R&D	—	$3.85B	$4.63B	$5.23B	$5.85B	+11.0%
SG&A	—	$2.12B	$2.63B	$2.95B	$2.70B	+6.3%

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
AAPL	Apple Inc.	5T	41.0x	11.0x	104.3%	+6.8%	+58.6%	Sell
ABNB	Airbnb Inc.	90.8B	37.5x	7.2x	15.9%	+29.9%	+7.6%	Hold
ADBE	Adobe Inc.	104.7B	15.1x	4.2x	60.7%	+11.9%	-28.7%	Strong Buy
ABBV	AbbVie Inc.	465.2B	129.7x	7.4x	14.4%	+4.6%	+44.0%	Hold
ABT	Abbott Laboratories	186.9B	34.9x	4.0x	7.9%	+3.0%	-12.5%	Strong Buy
AMGN	Amgen Inc.	209.2B	27.0x	5.6x	19.1%	+8.1%	+32.5%	Strong Buy

All REGN indicators

Market & fundamental data

Available fields

275

Groups with data

Currency

USD

Showing 275 of 275 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0000872589
Company name	Regeneron Pharmaceuticals, Inc.
Country	United States
Country code	US
Cusip	75886F107
Employees	15,410
Employees Change	304%
Employees Change Percent	2.01
Enterprise value	$50.9B
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
In Index	SP500, NASDAQ100
Industry	Biotechnology
IPO Date	1991-04-02
Isin	US75886F1075
Last refreshed	2026-07-27
Market cap	$66.7B
Market cap category	Large-Cap
Price	$656
Price currency	USD
Rev Per Employee	968,176.51x
Sector	Healthcare
Sector PE	44.88
Sector PE Fwd	23.79
Sic	2834
Symbol	REGN
Website	https://www.regeneron.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	6.63%
EV Earnings	11.51x
EV Sales Forward	3.12x
EV/EBIT	14.03x
EV/EBITDA	12.21x
EV/FCF	12.38x
EV/Sales	3.41x
FCF yield	6.16%
Forward P/E	13.73x
P/B ratio	2.13x
P/E ratio	15.98x
P/S ratio	4.47x
PE Ratio10 Y	22.18x
PE Ratio3 Y	19.49x
PE Ratio5 Y	16.67x
PEG ratio	1.27x
PS Forward	4.09x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	24.32%
EBITDA Margin	27.94%
FCF margin	27.57%
Gross margin	43.89%
Gross Profit	$6.5B
Gross Profit Growth	-4.75%
Gross Profit Growth Q	12.57%
Gross Profit Growth3 Y	-1.77%
Gross Profit Growth5 Y	5.15%
Net Income	$4.4B
Net Income Growth	-1.69%
Net Income Growth Q	-10.08%
Net Income Growth Years	2%
Net Income Growth3 Y	1.88%
Net Income Growth5 Y	2.01%
Pretax Margin	34.56%
Profit Margin	29.65%
Profit Per Employee	$287,047
Profitable Quarters	$57
Profitable Years	14
ROA	6.13
Roa5y	11.91
ROCE	10.15
ROE	14.55
Roe5y	24.44
ROIC	12.93
Roic5y	28.16

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	5.39%
Cagr15y	17.69%
Cagr1y	15.25%
Cagr20y	22.67%
Cagr3y	-3.44%
Cagr5y	2.44%
EPS Growth	4.14
EPS Growth Q	-7.15
EPS Growth Years	2
EPS Growth3 Y	3.75
EPS Growth5 Y	3.17
FCF Growth	32.6%
FCF Growth Q	3.98%
FCF Growth3 Y	4.02%
FCF Growth5 Y	15.18%
OCF Growth	26.8%
OCF Growth Q	3.23%
OCF Growth10 Y	12.99%
OCF Growth3 Y	5.4%
OCF Growth5 Y	14.13%
Revenue Growth	5.92x
Revenue Growth Q	19.04x
Revenue Growth Quarters	4x
Revenue Growth Years	3x
Revenue Growth3 Y	6.45x
Revenue Growth5 Y	10.16x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.38
Assets	$40.9B
Cash	$8.8B
Current Assets	$18.2B
Current Liabilities	$5.1B
Debt	$2.7B
Debt EBITDA	$0.65
Debt Equity	$0.09
Debt FCF	$0.66
Equity	$31.4B
Interest Coverage	75.61
Liabilities	$9.4B
Long Term Assets	$22.7B
Long Term Liabilities	$4.3B
Net Cash	$15.8B
Net Cash By Market Cap	$23.72
Net Cash Growth	6.12%
Net Debt EBITDA	$-3.8
Net Debt Equity	$-0.5
Net Debt FCF	$-3.85
Tangible Book Value	$30.1B
Tangible Book Value Per Share	$296
WACC	5.39

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	3.57
Inventory Turnover	2.66
Net Working Capital	$5.1B
Quick ratio	2.84
Working Capital	$13.1B
Working Capital Turnover	$1.1

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	5.61%
Dividend Growth	0%
Dividend Growth Years	0%
Dividend per share	$3.76
Dividend Years	2
Dividend Yield	0.57%
Ex Div Date	2026-05-20
Last Dividend	$0.94
Payout Frequency	Quarterly
Payout Ratio	8.86%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	69.02%
1Y total return	15.24%
200-day SMA	706.1
3Y total return	-9.96%
50-day SMA	640.3
50-day SMA vs 200-day SMA	50under200
5Y total return	12.8%
All Time High	1,211.2
All Time High Change	-45.84%
All Time High Date	2024-08-27
All Time Low	3
All Time Low Change	21,767%
All Time Low Date	1994-12-29
ATR	16.83
Beta	0.24
Beta1y	0.16
Beta2y	0.57
Ch YTD	-15.01
High	667.5
High52	821.1
High52 Date	2026-01-09
High52ch	-20.11%
Low	654.1
Low52	541
Low52 Date	2025-10-13
Low52ch	21.26%
Ma50ch	2.45%
Price vs 200-day SMA	-7.1%
RSI	51.11
RSI Monthly	45.88
RSI Weekly	44.51
Sharpe ratio	0.47x
Sortino ratio	0.9
Total Return	6.18%
Tr YTD	-14.78
Tr15y	1,050.91%
Tr1m	6.15%
Tr1w	-3.06%
Tr3m	-14.23%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	27
Analyst Count Top	18
Analyst Price Target Top	$805
Analyst Ratings	Buy
Analyst Ratings Top	Buy
Earnings EPS Estimate	$10.34
Earnings EPS Estimate Growth	-19.78
Earnings Revenue Estimate	3,814,372,584x
Earnings Revenue Estimate Growth	3.65x
Operating Income	$3.8B
Operating Income Growth	-3.33
Operating Income Growth Q	23.31
Operating Income Growth3 Y	-6.56
Operating Income Growth5 Y	-0.75
Operating margin	25.76
Price target	$819
Price Target Change	$24.87
Price Target Change Top	$22.68

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	97,667,683%
Float Percent	96%
Shares Insiders	3.82%
Shares Institutions	91.18%
Shares Out	101,739,032
Shares Qo Q	0.19%
Shares Yo Y	-5.61%
Short Float	3.58%
Short Ratio	3.2
Short Shares	3.43

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$3.1B
Average Volume	766,665.3x
Bv Per Share	308.3
CAPEX	$-899.7M
Ch10y	67.63
Ch15y	1,041.5
Ch1m	6.15
Ch1w	-3.06
Ch1y	14.61
Ch20y	5,799.4
Ch3m	-14.36
Ch3y	-10.7
Ch5y	11.88
Ch6m	-12.94
Change	0.63%
Change From Open	-0.35
Close	651.9
Days Gap	0.98
Depreciation Amortization	540,000,000
Dollar Volume	464,682,059.5
Earnings Date	2026-07-30
Earnings Time	bmo
EBIT	$3.6B
EBITDA	$4.2B
EPS	$41.06
F Score	4
FCF	$4.1B
FCF EV Yield	8.08x
FCF Per Share	$40.43
Financing CF	-3,428,400,000
Fiscal Year End	December
Founded	1,988
Graham Number	533.71513
Graham Upside	-18.64
Income Tax	$733.5M
Investing CF	-1,705,500,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-04-29
Last Report Date	2026-03-31
Last Split Type	Never
Last10k Filing Date	2026-02-04
Lynch Fair Value	$205
Lynch Upside	-68.7
Ma150	719.2
Ma150ch	-8.78%
Ma20	656.7
Ma20ch	-0.11%
Net CF	-122,400,000
Next Earnings Date	2026-07-30
Open	658.3
Optionable	Yes
P FCF Ratio	16.23
P OCF Ratio	13.31
Payment Date	2026-06-04
Position In Range	14.57
Ppne	5,266,100,000
Price Date	2026-07-24
Price EBITDA	$16.01
Ptbv Ratio	2.21
Relative Volume	0.92x
Revenue	14,919,600,000x
SBC By Revenue	6.67x
Share Based Comp	995,400,000
Tax By Revenue	4.92x
Tax Rate	14.22%
Tr20y	5,848.1%
Tr6m	-12.71%
Us State	New York
Volume	708,346
Z Score	6.53

Frequently asked questions

About this REGN report

What is the latest published REGN stock rating?

Regeneron Pharmaceuticals Inc. is shown with strong buy in the latest published report, analyzed 2026-05-10. The hub links directly to the full analysis surface where the dated rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full REGN analysis?

The full latest published report, analyzed 2026-05-10, lives at /stocks/REGN/analysis. The bare ticker page summarizes that read and links to each analysis tab; earlier editions remain under /analysis/archive.

What fair-value range is used for REGN?

The latest published report analyzed 2026-05-10 frames REGN around USD 917 to USD 1,505. This is a dated valuation range, not a live market price; check the valuation, sensitivity, and bear-case tabs before making a decision.

How often is the REGN page updated?

The hub selects the latest published stock report regardless of age and displays its analysis date (2026-05-10). Separately sourced market data is labeled with its own recorded timestamp and is never inferred from the report.

Regeneron Pharmaceuticals Inc. (REGN)

Coverage state: Latest published research available

Generate a fresh REGN analysis

Our latest published analysis: REGN rated Strong Buy

Price

Financial snapshot

Fair-value bridge

Analyst consensus

Latest news · REGN

Valuation

Profitability

Balance sheet

Trading

Position sizing & entry playbook

Next earnings

Sector percentile context

All REGN indicators

Profile and market data

Valuation

Profitability

Growth

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Analyst estimates

Ownership and float

Other indicators

Deeper analysis on REGN

Frequently asked questions